1 day+1.45%
1 week+9.38%
Current month+13.82%
1 month+69.08%
3 months+85.19%
6 months+81.11%
1 week 129
Extreme 129
152.5
1 month 83.6
Extreme 83.6
153.5
Current year 37.55
Extreme 37.55
153.5
1 year 37.55
Extreme 37.55
153.5
3 years 37.55
Extreme 37.55
153.5
5 years 37.55
Extreme 37.55
153.5
10 years 37.55
Extreme 37.55
153.5
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2017-01-12
Chief Executive Officer - 2017-01-12
Director of Finance/CFO - 2019-09-22
Director TitleAgeSince
Director/Board Member 52 2019-07-24
Chairman - 2017-01-12
Director/Board Member - 2025-10-22
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%+9.38% - - 588M
-0.56%-8.30%-5.88%+10.58% 46.38B
-2.08%-2.81%+396.70%+533.09% 44.51B
+0.12%-2.48%+35.68%+20.50% 42.3B
-2.62%-5.52%-2.66%+77.44% 39.91B
-1.26%-2.95%+12.00%+40.55% 32.79B
+0.16%-2.27% - - 17.13B
-0.54%-1.66%+20.09%+115.10% 16.36B
-0.03%-2.56%+10.88%+30.90% 14.31B
-1.92%-6.43%+73.47%+36.68% 13.29B
Average -0.73%-2.70%+67.54%+108.10% 26.76B
Weighted average by Cap. -1.09%-3.24%+82.62%+129.36%

Financials

2024 2025
Net sales 803K 25.4K 21.85K 20.63K 18.77K 35.08K 2.42M 35.51K 246K 94.46K 1.23M 95.36K 93.27K 3.92M 50.29M 1.59M 1.37M 1.29M 1.18M 2.2M 152M 2.22M 15.38M 5.92M 77.18M 5.97M 5.84M 246M
Net income -440M -13.93M -11.98M -11.31M -10.29M -19.23M -1.33B -19.47M -135M -51.8M -676M -52.29M -51.14M -2.15B -1.11B -35M -30.11M -28.42M -25.87M -48.33M -3.34B -48.93M -338M -130M -1.7B -131M -129M -5.4B
Net Debt - -
Logo Elixiron Immunotherapeutics (Cayman) Limited
Elixiron Immunotherapeutics Cayman Ltd is an investment holding company located in Taiwan, focusing on developing innovative precision immunotherapy drugs for multiple diseases. The Company operates as a new drug research and development enterprise, with products currently in clinical development. Its pipeline is centered on innovative drug development, covering neurodegenerative disorders, immune-related diseases, and oncology. The main clinical-stage candidates are EI-1071 (Enrupatinib) and EI-001 (Indemakitug). EI-1071 (Enrupatinib) is a proprietary small-molecule drug targeting neurodegenerative diseases, with Alzheimer’s disease as its primary indication, currently in Phase II clinical trials. EI-001 (Indemakitug) is an anti-IFNy monoclonal antibody designed for precise immunomodulation in autoimmune diseases.
Employees
-
Date Price Change Volume
26-09-10 NT$140.00 +1.45% 911,318
26-09-09 NT$138.00 -1.08% 1,505,241
26-09-08 NT$139.50 -4.12% 2,296,666
26-09-07 NT$145.50 +4.68% 3,860,087
26-09-04 NT$139.00 +7.75% 2,406,024
  1. Stock Market
  2. Stocks
  3. 7871 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!